| 2020 ESC Core Curriculum for the Cardiologist: What has changed? Why? Should we also change our curriculum? | Aylin YILDIRIR | 717–720 |
| Galectin-3 for risk stratification in acute coronary syndrome | Kaan OKYAY | 721–722 |
| The relationship between galectin-3 and SYNTAX Score I in patients with non-ST-segment elevation myocardial infarction | Alaa Quisi, Hazar HARBALIOĞLU, Gökhan ALICI, Ömer GENÇ, İbrahim Halil KURT | 723–730 |
| The validity and reliability of the Turkish version of the Seattle Angina Questionnaire | Fırat ULUTATAR, Mehmet Tuncay DURUÖZ, Canan Şanal TOPRAK, Anwar SUHAİMİ, Mehmet AĞIRBAŞLI | 731–738 |
| Evaluation of aortic distensibility in patients with mitral valve prolapse using echocardiography and applanation tonometry | Cevat KIRMA, Süleyman EFE, Onur TAŞAR, Can Yücel KARABAY, Sedat KALKAN | 739–745 |
| Evaluation of the relationship between erectile dysfunction and epicardial fat tissue thickness and carotid intima-media thickness in patients with newly diagnosed hypertension | Abdullah GÜREL, Yaşar TURAN, Taner SARAK, Hüseyin EDE, Davut KARAKURT, İsa ARDAHANLI | 746–753 |
| Percutaneous angioplasty in the treatment of thrombosed hemodialysis fistulas: A single-center experience with 1 year of follow-up | Savaş SİPAHİ, Ahmed Bilal GENÇ, Selçuk YAYLACI, Hamad DHEİR, Salih ŞAHİNKUŞ, Muhammed Necati Murat AKSOY, İbrahim KOCAYİĞİT, Ersan TATLI, Mustafa Tarık AĞAÇ | 754–759 |
| Is it possible to reduce radiation exposure during transcatheter atrial septal defect closure in children? | Selman GÖKALP, Erkut ÖZTÜRK, Alper GÜZELTAŞ, İbrahim Cansaran TANIDIR, Erman ÇİLSAL, Mehmet Akın TOPKARCI | 760–765 |
| Successful dilatation of underexpanded stent with super-high-pressure balloon: A case report | Edin Begic, Mesud Jamakovic, Kenana Aganovic | 766–770 |
| Transcatheter treatment of partial anomalous pulmonary venous connection to left subclavian vein | Hasan ARI, Fahriye VATANSEVER, Mehmet MELEK, Selma ARI, Tahsin BOZAT | 771–774 |
| Obstructive mechanical mitral valve thrombosis and gastric adenocarcinoma: A therapeutic dilemma |